Cantor Fitzgerald Weighs in on FATE FY2026 Earnings

Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Fate Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the biopharmaceutical company will post earnings per share of ($0.73) for the year. The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share.

Several other research analysts also recently commented on the stock. Stifel Nicolaus decreased their price target on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research note on Thursday, March 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Thursday. Wall Street Zen upgraded Fate Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 15th. Robert W. Baird lowered their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Finally, Wells Fargo & Company decreased their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. Eight research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Fate Therapeutics has a consensus rating of "Hold" and a consensus price target of $4.14.

Fate Therapeutics Stock Performance

FATE traded down $0.15 during trading on Tuesday, reaching $1.40. The stock had a trading volume of 2,168,047 shares, compared to its average volume of 2,244,646. The business has a 50-day moving average of $1.18 and a 200-day moving average of $1.38. Fate Therapeutics has a one year low of $0.66 and a one year high of $5.92. The stock has a market cap of $160.45 million, a PE ratio of -0.85 and a beta of 2.23.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $1.63 million during the quarter, compared to the consensus estimate of $1.18 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.

Institutional Trading of Fate Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of FATE. Intech Investment Management LLC raised its position in shares of Fate Therapeutics by 27.5% during the 4th quarter. Intech Investment Management LLC now owns 39,443 shares of the biopharmaceutical company's stock valued at $65,000 after buying an additional 8,497 shares during the period. SG Americas Securities LLC raised its stake in Fate Therapeutics by 30.6% during the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 10,511 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Fate Therapeutics by 6.6% in the 4th quarter. American Century Companies Inc. now owns 197,704 shares of the biopharmaceutical company's stock valued at $326,000 after purchasing an additional 12,295 shares during the last quarter. Franklin Resources Inc. increased its stake in Fate Therapeutics by 9.6% in the fourth quarter. Franklin Resources Inc. now owns 165,353 shares of the biopharmaceutical company's stock valued at $273,000 after purchasing an additional 14,532 shares during the period. Finally, ProShare Advisors LLC increased its holdings in shares of Fate Therapeutics by 77.9% in the fourth quarter. ProShare Advisors LLC now owns 33,645 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 14,728 shares during the period. Hedge funds and other institutional investors own 97.54% of the company's stock.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.